Source: Tech – South China Morning PostSales of weight-loss drugs in the West have soared in recent years, driven by the approval of a new class of more effective medication, the rapid growth in obese populations owing to poor diet and lack of exercise, and endorsements by celebrities and social media influencers.
In China, over 60 late-stage drugs are undergoing clinical trials. In the coming years, these may compete with the products of incumbents such as Denmark’s Novo Nordisk and US-based Eli Lilly, Boston-based global…Read More